miRagen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.

Patents 181show all

  • 73
    C12N - Microorganisms or enzymes
  • 45
    A61K - Preparations for medical, dental, or toilet purposes
  • 9
    C07H - Sugars
  • 6
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 6
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 5
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 4
    C07J - Steroids
  • 4
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture

Clinical Trials 15show all

12Phase 23Phase 1

SEC Filings show all


8
D

Contact Information

Boulder, CO
United States

SEC Form D Funding Events

DateOfferedSoldType
2015-02-17$20,000,000$8,499,962Other
2014-06-26$19,999,866$12,999,906Equity
2012-01-03$6,000,000$6,000,000Security to be Acquired, Other
2009-05-27$11,999,997$11,999,997Equity
2009-05-27$52,983$52,983Equity
2009-01-28Unknown Unknown Other (Paper Filing)

Key Executives

  • William S. Marshall
    Executive Officer, Director
  • Marvin Caruthers
    Director
  • Kyle Lefkoff
    Director
  • Bruce Booth
    Executive Officer, Director
  • Thomas Hughes
    Director
  • Jason Leverone
    Executive Officer
  • John Creecy
    Director
  • Christopher J Morl
    Executive Officer
  • David M. Rodman
    Executive Officer
  • Jason A Leverone
    Executive Officer
  • David Rodman
    Executive Officer